These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 22691112)
1. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112 [TBL] [Abstract][Full Text] [Related]
2. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423 [TBL] [Abstract][Full Text] [Related]
3. Tiotropium Respimat inhaler and the risk of death in COPD. Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P; N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515 [TBL] [Abstract][Full Text] [Related]
4. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
6. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients. Ichinose M; Fujimoto T; Fukuchi Y Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446 [TBL] [Abstract][Full Text] [Related]
7. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Keating GM Drugs; 2014 Oct; 74(15):1801-16. PubMed ID: 25300412 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642 [TBL] [Abstract][Full Text] [Related]
9. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes. Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898 [TBL] [Abstract][Full Text] [Related]
11. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials. Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728 [TBL] [Abstract][Full Text] [Related]
12. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322 [TBL] [Abstract][Full Text] [Related]
13. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD. Hodder R; Pavia D; Lee A; Bateman E Int J Chron Obstruct Pulmon Dis; 2011; 6():245-51. PubMed ID: 21814460 [TBL] [Abstract][Full Text] [Related]
14. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455 [TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929 [TBL] [Abstract][Full Text] [Related]
16. Tiotropium versus placebo for chronic obstructive pulmonary disease. Karner C; Chong J; Poole P Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525 [TBL] [Abstract][Full Text] [Related]
17. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease. Tang Y; Massey D; Zhong NS Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149 [TBL] [Abstract][Full Text] [Related]
20. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study. Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]